pemphigus vulgaris
Information
- Disease name
- pemphigus vulgaris
- Disease ID
- DOID:0060851
- Description
- "A pemphigus characterized by autosomal dominant blisters and erosions on the skin and mucous membranes erosions cause by autoantibodies to intercellular cement substance." [url:https\://www.ncbi.nlm.nih.gov/pubmed/2217197, url:https\://www.ncbi.nlm.nih.gov/pubmed/4577497]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT06167408 | Completed | Identifying Factors Influencing In-Hospital Relapse in Pemphigus Patients | January 1, 2022 | June 1, 2022 | |
| NCT00135720 | Completed | Phase 2 | Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris | June 2004 | November 2007 |
| NCT00606749 | Completed | Phase 2 | Use of KC706 for the Treatment of Pemphigus Vulgaris | November 2007 | June 2008 |
| NCT00626678 | Completed | Phase 2 | Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone | January 2008 | September 2010 |
| NCT02383589 | Completed | Phase 3 | A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV) | May 26, 2015 | October 29, 2019 |
| NCT02704429 | Completed | Phase 2 | A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris | January 22, 2016 | January 10, 2020 |
| NCT03334058 | Completed | Phase 2 | A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus | October 18, 2017 | October 28, 2020 |
| NCT04540133 | Completed | Phase 2 | Dexamethasone Solution and Dexamethasone in Mucolox™ | December 26, 2020 | January 6, 2023 |
| NCT04598451 | Completed | Phase 3 | A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) | December 1, 2020 | August 22, 2023 |
| NCT05000216 | Completed | Phase 2 | COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders | August 13, 2021 | March 28, 2024 |
| NCT00063752 | Completed | Phase 1 | Safety Study of PI-0824 to Treat Pemphigus Vulgaris | July 2003 | March 2005 |
| NCT05594472 | Recruiting | Phase 3 | Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid | November 1, 2022 | June 30, 2023 |
| NCT04422912 | Recruiting | Phase 1 | A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) | September 29, 2020 | January 2029 |
| NCT02753777 | Recruiting | Autoimmune Blistering Diseases Study | April 2016 | January 2, 2025 | |
| NCT05635266 | Recruiting | Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives | October 26, 2021 | October 2025 | |
| NCT00429533 | Terminated | Phase 2 | Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris | November 1996 | February 2004 |
| NCT03239470 | Terminated | Phase 1 | Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus | October 10, 2017 | January 9, 2023 |
| NCT03075904 | Terminated | Phase 1/Phase 2 | A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) | July 18, 2017 | January 16, 2019 |
| NCT00483119 | Terminated | Phase 2 | Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus | April 2007 | February 2011 |
| NCT01920477 | Terminated | Phase 3 | Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris | August 13, 2013 | January 11, 2018 |
| NCT01930175 | Terminated | Phase 2 | Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris | December 18, 2013 | September 25, 2019 |
| NCT04598477 | Terminated | Phase 3 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) | July 15, 2021 | March 25, 2024 |
| NCT04117529 | Unknown status | N/A | Phenotypic and Functional Characterisation of Human B-cell Response in Pemphigus | October 22, 2019 | July 2022 |
| NCT05303272 | Unknown status | Phase 4 | A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV) | February 1, 2021 | September 30, 2022 |
| NCT04096222 | Unknown status | Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients | June 29, 2021 | March 28, 2023 | |
| NCT05338112 | Unknown status | Role of Tzanck Smear in Determining Pemphigus Vulgaris Disease Activity | January 1, 2022 | April 15, 2023 | |
| NCT04023149 | Unknown status | Phase 2 | Efficacy of Interleukin-2 Gargle in the Treatment of Oral Mucosa Lesion in Pemphigus Vulgaris | April 2, 2020 | December 1, 2021 |
| NCT03177213 | Unknown status | Serum IL-21 Levels in Patients With Pemphigus Vulgaris | June 2017 | December 2018 | |
| NCT03780166 | Withdrawn | Phase 2 | A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris | March 2019 | November 2020 |
- Disase is a (Disease Ontology)
- DOID:9182
- Cross Reference ID (Disease Ontology)
- GARD:7355
- Cross Reference ID (Disease Ontology)
- ICD10CM:L10.0
- Cross Reference ID (Disease Ontology)
- MESH:D010392
- Cross Reference ID (Disease Ontology)
- MIM:169610
- Cross Reference ID (Disease Ontology)
- NCI:C34910
- Cross Reference ID (Disease Ontology)
- ORDO:704
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:49420001
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0030809
- Exact Synonym (Disease Ontology)
- familial pemphigus vulgaris
- OrphaNumber from OrphaNet (Orphanet)
- 704
- ICD10 preferred id (Insert disease from ICD10)
- D0009654
- ICD10 class code (Insert disease from ICD10)
- L10.0